Acceder

Publicaciones - ONCOLOGÍA CLÍNICA Y TRASLACIONAL

Cargando...
Garcia del Muro, Xavier; Riva, Francois; Andres Cuellar, M.; Maroto-Rey, Pablo; Castellano, Daniel E.; Giannatempo, Patrizia; Climent Duran, Miguel Angel A.; Necchi, Andrea; Perez-Valderrama, Begona; De Liano Lista, Alfonso Gomez; Garcias-Espana, Carmen; Puente, Javier; Ros, Silverio; Santander, Carmen; Masini, Cristina; Martinez de Falcon, Marta; Garcia, Almudena; Sampayo-Cordero, Miguel; Malfettone, Andrea; Paez, David. A phase 2 study of the efficacy and safety of INCMGA00012 in advanced penile squamous cell carcinoma (PSqCC): ORPHEUS.. JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(6). 10.1200/JCO.2022.40.6_suppl.TPS8
AÑO: 2022; IF: 45.3
Encarnacion JA, Cerezuela P, Espanol I, Garcia MR, Manso C, De la Fuente I, Garrigos N, Viney A, Minguillon J, Surralles J. Fanconi-like anemia related to a FANCM mutation. Eur J Med Genet. 2022 Jan;65(1):104399. doi: 10.1016/j.ejmg.2021.104399. Epub 2021 Nov 15. PubMed PMID: 34793962.
AÑO: 2022; IF: 1.9
Castillo-Guardiola V, Rosado-Jimenez L, Sarabia-Meseguer MD, Marin-Vera M, Macias-Cerrolaza JA, Garcia-Hernandez R, Zafra-Poves M, Sanchez-Henarejos P, Moreno-Locubiche MA, Cuevas-Tortosa E, Arnaldos-Carrillo M, Ayala de la Pena F, Alonso-Romero JL, Noguera-Velasco JA, Ruiz-Espejo F. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance. Eur J Med Genet. 2022 Apr;65(4):104468. doi: 10.1016/j.ejmg.2022.104468. Epub 2022 Mar 1. PubMed PMID: 35245693.
AÑO: 2022; IF: 1.9
Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Ciruelos EM, Munoz M, Bermejo B, Margeli M, Csoszi T, Anton A, Turner N, Casas MI, Morales S, Alba E, Calvo L, de la Haba-Rodriguez J, Ramos M, Murillo L, Santaballa A, Alonso-Romero JL, Sanchez-Rovira P, Corsaro M, Huang X, Thallinger C, Kahan Z, Gil-Gil M. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. Eur J Cancer. 2022 Jun;168:12-24. doi: 10.1016/j.ejca.2022.03.006. Epub 2022 Apr 13. PubMed PMID: 35429901.
AÑO: 2022; IF: 8.4
Garcia-Saenz JA, Martinez-Janez N, Cubedo R, Jerez Y, Lahuerta A, Gonzalez-Santiago S, Ferrer N, Ramos M, Alonso-Romero JL, Anton A, Carrasco E, Chen J, Neuwirth R, Galinsky K, Vincent S, Leonard EJ, Slamon D. Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor. Clin Cancer Res. 2022 Mar 15;28(6):1107-1116. doi: 10.1158/1078-0432.CCR-21-2652. PubMed PMID: 34980598; PubMed Central PMCID: PMC9365359.
AÑO: 2022; IF: 11.5
< AnteriorSiguiente >

Instituto de Investigación Sanitaria Acreditado

ISCII